53.33
Schlusskurs vom Vortag:
$52.66
Offen:
$52.53
24-Stunden-Volumen:
526.90K
Relative Volume:
0.46
Marktkapitalisierung:
$4.10B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-13.50
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
-1.02%
1M Leistung:
-8.88%
6M Leistung:
+26.08%
1J Leistung:
+0.45%
Merus N V Stock (MRUS) Company Profile
Firmenname
Merus N V
Sektor
Branche
Telefon
31 030 253 8800
Adresse
YALELAAN 62, 3584 CM UTRECHT
Vergleichen Sie MRUS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MRUS
Merus N V
|
53.33 | 4.10B | 35.93M | -244.56M | -157.31M | -3.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-13 | Eingeleitet | Piper Sandler | Overweight |
2025-02-07 | Eingeleitet | Wells Fargo | Overweight |
2024-11-21 | Eingeleitet | Goldman | Buy |
2024-10-24 | Eingeleitet | UBS | Buy |
2024-03-28 | Eingeleitet | Truist | Buy |
2024-03-04 | Bestätigt | Needham | Buy |
2023-11-02 | Eingeleitet | Canaccord Genuity | Buy |
2023-08-21 | Eingeleitet | TD Cowen | Outperform |
2022-08-02 | Eingeleitet | Stifel | Buy |
2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
2022-02-10 | Eingeleitet | Needham | Buy |
2021-11-17 | Fortgesetzt | Guggenheim | Buy |
2021-06-07 | Hochstufung | Citigroup | Neutral → Buy |
2021-04-08 | Eingeleitet | William Blair | Outperform |
2021-03-16 | Eingeleitet | SVB Leerink | Outperform |
2020-06-26 | Eingeleitet | H.C. Wainwright | Buy |
2020-05-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2019-11-20 | Fortgesetzt | Guggenheim | Buy |
2019-06-28 | Eingeleitet | ROTH Capital | Buy |
2019-04-12 | Fortgesetzt | Guggenheim | Buy |
2019-04-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2019-03-27 | Eingeleitet | Berenberg | Buy |
2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
2017-03-21 | Herabstufung | Citigroup | Buy → Neutral |
2016-12-22 | Hochstufung | Citigroup | Neutral → Buy |
2016-11-07 | Herabstufung | Citigroup | Buy → Neutral |
2016-06-13 | Eingeleitet | Citigroup | Buy |
2016-06-13 | Eingeleitet | Guggenheim | Buy |
2016-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Merus N V Aktie (MRUS) Neueste Nachrichten
Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN
(MRUS) Technical Data - news.stocktradersdaily.com
Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential By Investing.com - Investing.com South Africa
Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential - Investing.com Nigeria
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha
The Netherlands: Merus raises US$300m from underwritten public offering - Investors in Healthcare
Why Merus N.V. (MRUS) Crashed On Wednesday - MSN
Merus N.V. announces proposed public offering of common shares - MSN
Merus dips 7%, prices $300M stock at $57 per share - MSN
Merus Announces Public Offering of Common Shares - TipRanks
Merus Raises $300m After ASCO Success - insights.citeline.com
Sector Update: Health Care Stocks Mixed Premarket Wednesday - marketscreener.com
MRUS: Joint Managers Lead Successful Offering | MRUS Stock News - GuruFocus
Merus Prices $300 Million Stock Offering - marketscreener.com
Merus N.V. (MRUS) Launches $300M Public Offering - GuruFocus
Merus N.V. announces public offering of common shares By Investing.com - Investing.com South Africa
Merus Prices 5.26 Mln Shares At $57/Shr In Public Offering; To Raise Around $300 Mln - Nasdaq
Merus N.V. Announces Pricing of Public Offering of Common Shares - The Manila Times
Merus N.V. Announces Proposed Public Offering of Common Shares | - GuruFocus
Merus (MRUS) Initiates Public Offering to Fund Development | MRU - GuruFocus
Merus (MRUS) Initiates Public Offering to Fund Development | MRUS Stock News - GuruFocus
Merus N.V. announces public offering of common shares - Investing.com Australia
Merus Plans Public Share Offering - marketscreener.com
Drugmaker Merus slips after share offering launch - TradingView
Merus N.V. Announces Proposed Public Offering of Common Shares - GlobeNewswire
How to Take Advantage of moves in (MRUS) - news.stocktradersdaily.com
e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio? - Benzinga
Merus, N.V. Provides Updates on Clinical Development - marketscreener.com
Merus NV Stock Skyrockets 8%: Bull Run Intact or Peak Approaching? - Daily Chhattisgarh News
Merus Announces Promising Phase 2 Trial Results - TipRanks
ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer - Yahoo Finance
Merus to Present at Upcoming Investor Conferences - GlobeNewswire
Merus Showcases Next-Gen Cancer Antibody Platform at Two Premier Healthcare Conferences - Stock Titan
Merus stock holds $85 target, Buy rating at H.C. Wainwright - Investing.com
Merus stock holds $85 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com India
Merus (MRUS) Stock: Analysts Rally Behind Biotech After Cancer Treatment Breakthrough - CoinCentral
Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Merus (NASDAQ:MRUS) Given a $110.00 Price Target by BMO Capital Markets Analysts - Defense World
Lazard Asset Management LLC Takes Position in Merus (NASDAQ:MRUS) - Defense World
Merus (NASDAQ:MRUS) Price Target Raised to $110.00 - Defense World
BofA Maintains Buy Rating on Merus (MRUS), Lifts PT - Yahoo Finance
Merus N.V.’s SWOT analysis: promising cancer drug pipeline boosts stock outlook - Investing.com Australia
Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data - MSN
Finanzdaten der Merus N V-Aktie (MRUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Merus N V-Aktie (MRUS) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Silverman Peter B. | COO & GC |
Jun 20 '25 |
Sale |
52.76 |
34,000 |
1,793,840 |
0 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):